Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.49 |
| ▸ | CES1 | P23141 | 3/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP2 | P12104 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26508769 | 0.85 | IDO1 (0.40) | CES2CES1AKR1C3AKR1C2PTGS1 | |
| SCHEMBL28382462 | 0.83 | CES2 (0.38) | CES2CES1AKR1C3AKR1C2PTGS1 | |
| SCHEMBL30544188 | 0.82 | CES2 (0.47) | CES2CES1AKR1C3AKR1C2PSEN1 | |
| SCHEMBL5079887 | 0.82 | CES2 (0.47) | CES2CES1AKR1C3AKR1C2PSEN1 | |
| SCHEMBL7673470 | 0.82 | CES2 (0.47) | CES2CES1AKR1C3AKR1C2MME | |
| SCHEMBL29009883 | 0.80 | AKR1C3 (0.49) | AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL7970825 | 0.79 | CES2 (0.52) | CES2CES1AKR1C3AKR1C2PTGS1 | |
| SCHEMBL15092196 | 0.79 | CES2 (0.52) | CES2CES1AKR1C3AKR1C2PTGS1 | |
| SCHEMBL30968933 | 0.78 | CES2 (0.44) | CES2CES1AKR1C3AKR1C2KMT2A | |
| SCHEMBL1565587 | 0.78 | CES2 (0.44) | CES2CES1AKR1C3AKR1C2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9290487-B2 | Pharmaceutical composition for treating diabetes | AJINOMOTO CO., INC. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2774917-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | Ajinomoto Co., Inc. (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | CES2 1253/4885CES1 346/4885AKR1C3 463/4885 |
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | CES2 1253/4885CES1 346/4885AKR1C3 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.